No Data
No Data
No Data
No Data
No Data
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
Benzinga14:34 ET
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
WSJApr 23 14:54 ET
ProKidney Sinks 15%+, Snapping Five-Session Run-Up That Saw Biotech More Than Double in Less Than a Week
PROK sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
Jerry KronenbergApr 18 16:56 ET
ProKidney Stock Soars 30%+ Tuesday and Nearly 90% in Less Than a Week
ProKidney rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
Jerry KronenbergApr 16 17:37 ET
Alpine Immune Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 — TD Cowen Downgrades Buy → Hold 04/12/2024 0.9% Leerink Partners $42 → $65 Downgrades Outperf
BenzingaApr 16 06:44 ET
Express News | Alpine Immune Sciences Inc : TD Cowen Cuts to Hold From Buy
Moomoo 24/7Apr 16 01:54 ET
No Data
No Data